Ad26.COV2.S

BIOLOGICAL17 trials

Sponsors

Janssen Vaccines & Prevention B.V., Janssen Pharmaceutical K.K., Janssen Research & Development, LLC, National Institute of Allergy and Infectious Diseases (NIAID), ANRS, Emerging Infectious Diseases

Conditions

COVID-19COVID-19 PreventionCoronavirus DiseaseCoronavirus Disease-2019 (COVID-19) PreventionCovid-19Covid-19 PreventionHealthyJuvenile Dermatomyositis (JDM)

Phase 1

A Study of Ad26.COV2.S in Adults (COVID-19)

CompletedNCT04436276

Janssen Vaccines & Prevention B.V.Covid-19 Prevention

Start: 2020-07-15End: 2023-02-21Updated: 2025-02-04

A Study of Ad26.COV2.S in Adults (COVID-19)

CompletedNCT04509947

Janssen Pharmaceutical K.K.Healthy

Start: 2020-08-11End: 2021-11-16Updated: 2021-11-24

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

CompletedNCT04889209

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19

Start: 2021-05-28End: 2023-06-16Updated: 2025-04-20

A Study of Ad26.COV2.S in Healthy Adults (COVID-19)

CompletedNCT04894305

Janssen Vaccines & Prevention B.V.Healthy

Start: 2021-05-25End: 2021-12-08Updated: 2021-12-22

Phase 2

A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents

CompletedNCT04535453

Janssen Vaccines & Prevention B.V.Healthy

Start: 2020-08-28End: 2022-03-09Updated: 2023-06-22

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)

CompletedNCT04765384

Janssen Vaccines & Prevention B.V.COVID-19 Prevention

Start: 2021-08-27End: 2023-11-24Updated: 2025-05-25

A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2

CompletedNCT04999111

Janssen Vaccines & Prevention B.V.Coronavirus Disease

Start: 2021-08-06End: 2022-11-22Updated: 2025-02-04

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

TerminatedNCT05000216

National Institute of Allergy and Infectious Diseases (NIAID)Juvenile Dermatomyositis (JDM), Juvenile Idiopathic Arthritis (JIA), Multiple Sclerosis (MS) +6

Start: 2021-08-13End: 2024-03-28Updated: 2025-08-22

A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive

CompletedNCT05007080

Janssen Vaccines & Prevention B.V.Coronavirus Disease-2019 (COVID-19) Prevention

Start: 2021-09-27End: 2023-08-14Updated: 2025-02-04

Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

Active, not recruitingNCT05409261

ANRS, Emerging Infectious DiseasesCOVID-19, SARS CoV 2 Infection, Vaccine Adverse Reaction +1

Start: 2022-06-02End: 2025-03-31Updated: 2024-03-27

Phase 3

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

CompletedNCT04505722

Janssen Vaccines & Prevention B.V.Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol

Start: 2020-09-07End: 2023-03-31Updated: 2025-02-04

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

CompletedNCT04614948

Janssen Vaccines & Prevention B.V.Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19

Start: 2020-11-12End: 2023-06-18Updated: 2025-02-04

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

CompletedNCT04908722

Janssen Vaccines & Prevention B.V.COVID-19 Prevention

Start: 2021-06-18End: 2023-07-10Updated: 2025-02-04

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

CompletedNCT05091307

Janssen Vaccines & Prevention B.V.COVID-19 Prevention

Start: 2021-11-02End: 2022-11-15Updated: 2025-05-25

Sisonke Boost Open Label Study

Active, not recruitingPACTR202312739012205

South African Medical Research CouncilCovid-19

Start: 2021-11-01Target: 500000Updated: 2026-01-27

Unknown Phase

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

Janssen Research & Development, LLCHealthy

Updated: 2021-03-26

A phase 1, randomized, observer-blind study to compare the safety, reactogenicity, and Immunogenicity of Ad26.COV2.S at a single Dose of 5x10^10 vp in 2 different volumes in healthy adults

Active, not recruitingNL-OMON50855

Janssen-Cilagcoronavirus COVID-19

Start: 2021-05-25Target: 380Updated: 2025-09-08

Related Papers

Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.

2025-11-251 citations

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.

2025-10-011 citations

Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy

Human Vaccines & Immunotherapeutics2025-08-131 citations

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

Human Vaccines & Immunotherapeutics2025-01-272 citations

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial.

2025-01-071 citations

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.

2024-11-1212 citations

Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials

The Journal of Infectious Diseases2024-09-037 citations

Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease risk.

2024-08-08

The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review.

2024-08-0111 citations

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial

Vaccine2024-06-251 citations

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials

UNC Libraries2024-06-21

Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.

2024-05-044 citations

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.

2024-03-117 citations

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.

2023-07-1118 citations

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.

2023-06-235 citations

Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study)

BMJ Medicine2023-03-015 citations

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan

Vaccine2023-01-058 citations

A Plain Language Summary of the Janssen COVID-19 Vaccine Effectiveness and Safety as a Single Dose and with a Booster

Future Virology2022-09-14

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.

2022-09-1363 citations

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.

2022-06-20139 citations

13 more papers not shown